App-Quantinova.ai

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2negative hormone receptorpositive breast cancer and bone metastases.

Hope S. Rugo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Alpharadin

A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.

Robert E. Coleman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Alpharadin

Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.

Peter A. Fasching - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fulvestrant

SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).

Hope S. Rugo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Capecitabine

A Phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI4276 in patients with select HER2-expressing advanced solid tumors.

Erika Paige Hamilton - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for treatment of central nervous system (CNS) progression post-radiotherapy in patients (pts) with HER2-positive metastatic breast cancer (MBC): PATRICIA.

Nancy U. Lin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab emtansine

Biosensors to assess performance status in cancer (BioAPS Study).

Arvind Manohar Shinde - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).

Philippe Armand - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Adcetris

A Phase II Randomized, Placebo-Controlled Trial Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC ) Undergoing ChemoRadiation Therapy (CRT): A National Comprehensive Cancer Network-Sponsored Study.

Grace K. Dy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nintedanib

CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

Leora Horn - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

amrubicin (IV)

TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.

James Chih-Hsin Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

rociletinib

Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

Frank Griesinger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.

Emma Jane Dean - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

ONC201 kills breast cancer cells by inhibiting mitochondrial respiration

YE Greer - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TIC 10

Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors

Marco Ruella - International Society for Biological Therapy of Cancer (SITC) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Engineering adoptive T cell therapy for efficacy in ovarian cancer

Kristin G Anderson - American Association of Immunologists (AAI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hyper activation of poly(ADP-ribose) polymerase 1 initiates large-scale metabolic changes in a cellular model of glioblastoma

Anna M. Wilk - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

ribose

Metabolomics of Gleason score in prostate tumor tissue and serum

Kathryn Penney - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Global and targeted metabolomic profiling of colorectal cancer progression

Beatriz Sanchez-Espiridion - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Silibinin exhibits anti-cachectic and anti-cancerous property by modulating metabolic properties of pancreatic cancer cells

Surendra K. Shukla - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Silibinin

Filters

41730 Abstracts